NASDAQ: AMLXAmylyx Pharmaceuticals Inc Stock
$4.23+0.25 (+6.28%)
Updated Apr 21, 2025
AMLX Price
$4.23
Fair Value Price
N/A
Market Cap
$374.79M
52 Week Low
$1.58
52 Week High
$7.27
P/E
-0.95x
P/B
2.27x
P/S
2.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.37M
Earnings
-$301.74M
Gross Margin
-42.6%
Operating Margin
-345.81%
Profit Margin
-345.4%
Debt to Equity
0.18
Operating Cash Flow
-$168M
Beta
1.17
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AMLX Overview
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, for the treatment of ALS. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AMLX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AMLX
Ranked#314 of 462
Ranked#314 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important AMLX news, forecast changes, insider trades & much more!
AMLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMLX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMLX is good value based on its book value relative to its share price (2.27x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
AMLX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AMLX due diligence checks available for Premium users.
Valuation
AMLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.95x
Industry
-184.27x
Market
27.14x
AMLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.27x
Industry
4.04x
AMLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMLX's financial health
Profit margin
Revenue
-$665.0k
Net Income
-$37.5M
Profit Margin
5,646%
AMLX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AMLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$193.6M
Liabilities
$28.9M
Debt to equity
0.18
AMLX's short-term assets ($189.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMLX's short-term assets ($189.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$59.0M
Investing
$65.0M
Financing
$110.0k
AMLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AMLX vs Biotech Stocks
Amylyx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.